Soltis Investment Advisors LLC Acquires 302 Shares of Amgen Inc. (NASDAQ:AMGN)

Soltis Investment Advisors LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 14.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,376 shares of the medical research company’s stock after purchasing an additional 302 shares during the period. Soltis Investment Advisors LLC’s holdings in Amgen were worth $639,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in AMGN. Moneta Group Investment Advisors LLC lifted its position in Amgen by 83,875.6% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock valued at $1,980,571,000 after purchasing an additional 7,532,031 shares during the period. Norges Bank acquired a new position in Amgen during the 4th quarter valued at about $1,351,778,000. Price T Rowe Associates Inc. MD lifted its position in Amgen by 158.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,950,013 shares of the medical research company’s stock valued at $774,791,000 after purchasing an additional 1,806,456 shares during the period. Morgan Stanley raised its position in shares of Amgen by 12.9% in the 4th quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock valued at $3,493,471,000 after acquiring an additional 1,523,665 shares during the period. Finally, Franklin Resources Inc. raised its position in shares of Amgen by 50.7% in the 2nd quarter. Franklin Resources Inc. now owns 3,290,926 shares of the medical research company’s stock valued at $730,651,000 after acquiring an additional 1,106,980 shares during the period. 74.44% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 2,096 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $273.03, for a total value of $572,270.88. Following the completion of the transaction, the senior vice president now directly owns 10,874 shares of the company’s stock, valued at $2,968,928.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Amgen news, SVP Nancy A. Grygiel sold 2,096 shares of Amgen stock in a transaction on Monday, December 4th. The shares were sold at an average price of $273.03, for a total transaction of $572,270.88. Following the completion of the transaction, the senior vice president now directly owns 10,874 shares of the company’s stock, valued at $2,968,928.22. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Jonathan P. Graham sold 10,000 shares of Amgen stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $272.81, for a total transaction of $2,728,100.00. Following the transaction, the executive vice president now directly owns 28,078 shares of the company’s stock, valued at $7,659,959.18. The disclosure for this sale can be found here. 0.57% of the stock is owned by company insiders.

Amgen Price Performance

Shares of AMGN opened at $321.97 on Tuesday. The stock has a market capitalization of $172.31 billion, a P/E ratio of 22.88, a P/E/G ratio of 2.88 and a beta of 0.62. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company has a 50 day moving average of $292.82 and a 200-day moving average of $272.93. The company has a quick ratio of 2.56, a current ratio of 2.86 and a debt-to-equity ratio of 7.71.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 7th. Investors of record on Friday, February 16th will be paid a $2.25 dividend. The ex-dividend date of this dividend is Thursday, February 15th. This is a boost from Amgen’s previous quarterly dividend of $2.13. This represents a $9.00 annualized dividend and a dividend yield of 2.80%. Amgen’s dividend payout ratio (DPR) is currently 60.55%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on AMGN shares. Royal Bank of Canada upgraded shares of Amgen from a “sector perform” rating to an “outperform” rating and increased their price target for the company from $256.00 to $300.00 in a research report on Tuesday, December 12th. UBS Group cut their price target on shares of Amgen from $315.00 to $314.00 and set a “neutral” rating on the stock in a research report on Monday, January 29th. Argus increased their price target on shares of Amgen from $280.00 to $310.00 and gave the company a “buy” rating in a research report on Tuesday, October 17th. Morgan Stanley cut their price target on shares of Amgen from $300.00 to $291.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 1st. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $270.00 price target on shares of Amgen in a research report on Friday, October 20th. One analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $291.58.

Check Out Our Latest Stock Analysis on AMGN

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Recommended Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.